Paper Details

  1. Home
  2. Paper Details

Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.

Author: YoungR C

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study discusses the controversial management of early stage ovarian cancer with poor prognostic features, highlighting the use of paclitaxel and platinum agents in adjuvant chemotherapy trials and the ongoing research to determine the optimal number of chemotherapy cycles.
Paper Details　
Original Abstract of the Article :
The optimal management of early stage ovarian cancer with poor prognostic features remains controversial. On the basis of results of studies in advanced ovarian cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in combination with a platinum agent has become part of adjuvant ch...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/10952120

データ提供：米国国立医学図書館（NLM）

Optimal Chemotherapy Regimen for Early Stage Ovarian Cancer

The fight against [early stage ovarian cancer] is an ongoing battle, with researchers continuously seeking ways to improve treatment outcomes. This study investigates the optimal number of chemotherapy cycles for patients with high-risk early stage ovarian cancer. Researchers conducted a [Gynecologic Oncology Group] study comparing three cycles with six cycles of adjuvant [paclitaxel/carboplatin] in a group of patients. They found no significant difference in overall or progression-free survival between the two regimens, despite a slightly higher incidence of some side effects with the six-cycle regimen. It's like deciding how many days to trek across the desert - finding the right balance between effectiveness and potential risks is key.

Number of Cycles: No Significant Impact on Survival

The study's results suggest that the number of chemotherapy cycles (three versus six) does not significantly impact overall or progression-free survival in patients with high-risk early stage ovarian cancer. This finding could help to inform treatment decisions and potentially reduce the burden of chemotherapy for some patients. It's like discovering that a shorter route across the desert can lead to the same destination.

Navigating Cancer Treatment with Careful Consideration

This research provides valuable information for clinicians treating patients with early stage ovarian cancer. While the number of chemotherapy cycles might not significantly impact survival, it's essential to carefully consider individual factors and potential side effects when making treatment decisions. As a wise camel, I always say, it's important to balance caution and courage when navigating a challenging journey.

Dr.Camel's Conclusion

This study suggests that the number of chemotherapy cycles (three versus six) does not significantly impact overall or progression-free survival in patients with high-risk early stage ovarian cancer. However, careful consideration of individual patient factors and potential side effects remains crucial in treatment decision-making.

Date :
  1. Date Completed 2000-09-20
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

10952120

DOI: Digital Object Identifier

10952120

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.